Maintenance of adequate vitamin D serum levels has been linked to a variety of health benefi ts. Vitamin D defi ciency, defi ned as a serum 25-hydroxyvitamin D level Ͻ20 ng/mL, is becoming a common issue as our population ages and sun exposure is minimized. Vitamin D deficiency can lead to osteoporosis, muscle weakness, and increased risk of falls and fractures. Therefore, adequate vitamin D supplementation is essential. With many dosing options available, it is important for clinicians to know how best to treat vitamin D deficiency without causing harm to minimize the risk of falls and fractures.
VITAMIN D BACKGROUND
Vitamin D is a fat soluble, organic substance with a 4-ringed cholesterol backbone. Humans cannot innately synthesize vitamin D; consequently, it must be obtained from outside sources. Humans obtain vitamin D from sunlight exposure, diet, and dietary supplements. These sources provide vitamin D in an inactive form and the body subsequently metabolizes it into an active form. Vitamin D suffi ciency is measured by obtaining a serum calcidiol, 25-hydroxyvitamin D, level. Patients at high risk for developing vitamin D defi ciency should be screened, including elderly patients, patients with malabsorptive syndromes, patients on drugs known to increase calcitriol catabolism, patients with chronic kidney disease, and patients with inadequate sun exposure. While no consensus exists on the optimal 25-hydroxyvitamin D level, there are widely accepted defi nitions for insuffi ciency and defi ciency.
Vitamin D insuffi ciency is defi ned by most as levels 20 to 30 ng/mL and defi ciency as levels Ͻ20 ng/mL. Debate exists over how much vitamin D is considered suffi cient with regards to supplementation. 1, 10 Some references recommend achieving 25-hydroxyvitamin D levels of Ͼ30 ng/mL with supplementation while others recommend 20 to 30 ng/mL. 6 Levels у20 ng/mL have been shown to be effective at reducing risk of fractures and levels of 20 to 30 ng/mL seem to be necessary to decrease the risk of falls. 6, 11, 12 
VITAMIN D SUPPLEMENTATION
Vitamin D is commonly supplemented in 2 forms: ergocalciferol (vitamin D 2 ) and cholecalciferol (vitamin D 3 ). Many over the counter vitamin D supplements contain ergocalciferol and it is currently the only prescription strength product available. 10, 13 For many years, vitamin D 2 and D 3 were deemed to be equipotent. However, more recent evidence indicates that vitamin D 3 is more potent and better at raising and maintaining serum vitamin D levels. 13, 14 It has been demonstrated that vitamin D 3 is approximately 30% more potent than vitamin D 2 .
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For supplementation without defi ciency, most experts recommend 400 to 800 IU daily for patients younger than 50 years and 800 to 1000 IU daily for elderly patients.
14,15 Doses of 800 IU daily combined with calcium may be necessary to reduce the risk of fractures and doses of 1000 IU daily may be necessary to reduce falls. 10, 16, 17 Vitamin D dosing for treating defi ciency is dependent on the initial serum 25-hydroxyvitamin D level. Many dosing strategies have been used, including 400 to 2000 IU daily and 50,000 IU weekly to monthly. 14, 17 To increase compliance, annual high dose vitamin D supplementation has also been studied. 18, 19 Patients with advanced renal disease (chronic kidney disease stage 3 and 4) cannot adequately convert D 3 to the active form, calcitriol, therefore, these patients typically require supplementation. 20, 21 Patients with low serum 25-hydroxyvitamin D levels (Ͻ15 ng/mL) need high dose supplementation (50,000 IU) weekly for a number of weeks depending on the initial serum level (Table) . Vitamin D requirements generally increase as age increases due to decreased synthesis from the skin and decreased renal conversion to the active form. 10 After receiving supplementation, patients' vitamin D levels should be reassessed in 3 months to confi rm the defi ciency has been corrected. 6 Although rare, multiple serum 25-hydroxyvitamin D levels Ͼ150 ng/mL suggest intoxication. 1 Symptoms of intoxication include nausea, vomiting, constipation, weakness, falls, and weight loss. 
FALLS AND FRACTURES
Several trials have been performed to assess the potential benefi ts of vitamin D on musculoskeletal health. Most, but not all, have revealed that vitamin D supplementation improves strength and reduces falls and fractures. 16, 22, [24] [25] [26] In studies using doses of 700 to 800 IU of vitamin D 3 daily, the relative risk of hip fracture and nonvertebral fracture was reduced, by 26% and 23% respectively, as compared to calcium and placebo. 16 Another study used 800 IU of cholecalciferolϩ1200 mg of calcium daily versus 1200 mg of calcium alone. The calcium plus vitamin D group had a 49% reduction in falls. 25 A few studies have looked at using lower doses of vitamin D (400 IU daily) to achieve the same benefi ts. 23 These trials have not shown a reduced risk of fractures. Therefore the compilation of these results, as well as the data from other trials, indicate that there is a dose dependent relationship with vitamin D and that supplementation of at least 800 IU daily, and up to 1000 IU daily, is required to prevent falls and fractures. [4] [5] [6] [24] [25] [26] To increase medication compliance, 2 studies examined once yearly high doses of vitamin D. 18, 19 The most recent trial was a single-center, double-blind, randomized, placebo-controlled study of women 70 years and older at a high risk of hip fracture. Patients were randomly assigned to receive either a single oral dose of cholecalciferol at 500,000 IU or a matched placebo annually for 3 to 5 years. Patients were followed for 1 year after their last dose. There was a higher risk of fractures in the cholecalciferol group than in the placebo group, 171 versus 135 respectively, as well as a higher rate of falls (RRϭ1.15). The higher risk of falls and fractures occurred more commonly in the fi rst 3 months after the dose than at any other time. This led the authors to conclude that "among older community-dwelling women, annual oral administration of high-dose cholecalciferol resulted in an increased risk of falls and fractures." 18 The information from this study brought to light the fi ndings from an earlier study. In this double-blind, placebo-controlled study, men and women older than 75 years were randomly assigned to receive high dose (300,000 IU) ergocalciferol or placebo by intramuscular injection annually for 3 years. The study showed that the ergocalciferol group had a statistically signifi cant higher risk of wrist and hip fractures. At the time, this study had no proposed explanation for this other than random chance. 19 Both of these studies allude to the fact that too much vitamin D may lead to adverse effects. There are several proposed explanations for the increase risk of falls and fractures seen with single high dose administration. The most plausible explanation is a negative feedback mechanism that occurs from high dose vitamin D. When presented with high dose vitamin D, the enzymes in the liver that catabolize calcitriol may be upregulated thus leading to decreased levels. 27 Although 25-hydroxyvitamin D levels measured in a small subset of patients did not indicate high enough levels for intoxication, it cannot be ruled out that some of these patients experienced symptoms of an overdose early on. These symptoms may include muscle weakness and falls. 
THE BOTTOM LINE
• Vitamin D defi ciency is a common problem that can be overcome by appropriate screening and supplementation.
• The vitamin D dosage regimen selected should demonstrate benefi ts in decreasing the risk of falls and fractures, typically 800 to 1000 IU daily.
• The use of annual high-dose vitamin D should be avoided since these regimens have not been proven benefi cial and may actually be harmful.
• Compliance should be stressed to achieve full benefi ts of vitamin D supplementation.
• More randomized controlled trials are needed to assess the optimal vitamin D dosage regimen and serum 25-hydroxyvitamin D level to target.
